Chemicals & Small Molecules

SNX-482 (Legacy Tebubio ref. 282TP2118). Potent and selective, voltage-dependent R-type CaV2.3 calcium channel blocker (IC50 = 30 nM). Antinociceptive; inhibits nociceptive C-fibre and Aδ-fibre-evoked neuronal responses.

Sarafotoxin S6a (Legacy Tebubio ref. 282TP2119). Endothelin receptor agonist (EC50 values are 7.5 and > 150 nM for contraction of pig coronary artery and guinea pig aorta respectively). Nociceptive in vivo.

Sarafotoxin S6c (Legacy Tebubio ref. 282TP2120). Highly selective ETB endothelin receptor agonist (Ki values are 0.29 and 28000 nM at ETB and ETA receptors respectively).

Sauvagine (Legacy Tebubio ref. 282TP2121). Corticotropin-releasing factor (CRF) receptor agonist. Ki values are 9.4, 9.9, and 3.8 nM for inhibition of 125I-[D-Tyr1]astressin binding to hCRF-R1, rCRF-R2a and mCRF-R2b respectively.

Seglitide (Legacy Tebubio ref. 282TP2122). Peptide agonist for sst2 and sst5 somatostatin receptors. IC50/Kd values (nM) at cloned human somatostatin receptors are: > 1000 (sst1), 0.2 - 1.5 (sst2), 27 - 36 (sst3), > 127 (sst4), and 0.06 - 23 (sst5).

ShK-Dap22 (Legacy Tebubio ref. 282TP2123). Extremely potent KV1.3 channel blocker (Kd = 23 pM for mKV1.3 currents). Selective for KV1.3 over other mammalian potassium channels (IC50 values are 23, 1800, 10500, 37000 and 39000 pM for mKV1.3, mKV1.1, hKV1.6, mKV1.4 and rKV1.2 respectively, and >100000 pM for hKV1.5, mKV1.7, hKV3.1, rKV3.4 and hKCa4). Suppresses T cell activation in vitro (IC50 < 500 pM).

Somatostatin 1-28 (Legacy Tebubio ref. 282TP2124). Somatostatin receptor agonist, derived from the post-translational cleavage of prosomatostatin.

Somatostatin 1-28 acetate (Legacy Tebubio ref. 282TP2124L). Somatostatin 1-28 acetate circulates in human plasma. Approximately 46% of the total somatostatin-like immunoreactivity in plasma is due to Somatostatin 1-28 acetate.

Stressin I (Legacy Tebubio ref. 282TP2125). Potent and selective corticotropin releasing factor receptor-1 (CRF1) agonist (Ki values are 1.5 and 224 nM for CRF1 and CRF2 receptors respectively). Increases ACTH levels and increases faecal pellet output in vivo following i.p. administration.